Johnson & Johnson Seeks Expanded FDA Approval for Caplyta in Bipolar Mania

By Colin Kellaher

 

Johnson & Johnson has filed for expanded U.S. Food and Drug Administration approval for its Caplyta antipsychotic medication in bipolar mania.

J&J said the filing seeks approval of Caplyta for the treatment of manic or mixed episodes associated with bipolar I disorder in adults, adding that a green light would mark the fifth approved use of the drug in adults.

The New Brunswick, N.J., drugmaker last week said Caplyta had met its key goals in a second late-stage study in bipolar mania.

Caplyta, which is already approved for uses in depressive episodes associated with bipolar I or II disorder, schizophrenia and major depressive disorder, was the key assets in J&J's $14.6 billion acquisition of Intra-Cellular Therapies last year.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

November 19, 2026 08:52 ET (13:52 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.

Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.

Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.

Popular

Sponsor Center